J&J’s Darzalex Scores Again In Frontline Myeloma
But Challenger Arriving In 2020
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.